It's the second attempt for the rare disease company, which initially announced plans to merge with Candid Therapeutics before the immune drug developer was bought by UCB.
An article from
Emerging biotech
It’s the second attempt for rare disease company, which initially announced plans to merge with Candid Therapeutics before the immune drug developer was bought by UCB.
Published June 1, 2026
RallyBio announced plans to merge with Avenzo Therapeutics on June 1, 2026.
After being ditched by Candid, Rallybio finds Avenzo to take its Nasdaq listing
ASCO: With bispecifics on its heels, Incyte positions Monjuvi combo for first-line DLBCL
FDA oncology roundup: AbbVie’s rare cancer approval, AstraZeneca in breast cancer limbo - Pharmaceutical Technology
With Elahere building steam, AbbVie nets FDA nod for another ImmunoGen cancer asset
Outlook moves toward potential US nod for thrice-snubbed eye drug with FDA appeal win
AstraZeneca gains 2nd bladder cancer nod in key expansion for Imfinzi
A turning point for pancreatic cancer patients
GC Biopharma sells US vaccine unit to Eli Lilly in $1.5b deal
Eli Lilly Deepens Innovation Push Through New Biopharma Collaborations - Eli Lilly (NYSE:LLY)
ASCO: Lilly ties Retevmo to ‘dramatic’ outcomes in early-stage lung cancer with rare RET biomarker
Avenzo Therapeutics, one of the first biotechs to get major Western VC backing to in-license Chinese assets, will go public in a…
The success came two days after a Phase 3 setback for another experimental drug and helps improve the position of Voxzogo amid…
Pierre Fabre claims to now be “aligned” with U.S. regulators on the path forward for a twice-rejected treatment. Elsewhere,…
Tested in a condition known as ENPP1 deficiency, the treatment failed a trial goal that’s important to regulators, spurring…
Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close…
A deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved…
